Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Imatinib therapy was discontinued in 40 patients who had sustained undetectable BCR-ABL transcripts for 2 or more years, and close follow-up revealed approximately 50% remained with undetectable disease off treatment at 24 months.

Stopping Imatinib: When is Enough Enough?